GlassScriptPhysician profile
Sandra Lee Boyle
NPI 1134114853
$298.93
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2021: $18.83 · 2022: $85.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $76.01 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.94 | 2019 | |
| Cranial Technologies, INC | $29.28 | 2019-2022 | |
| Pfizer INC. | $27.45 | 2019 | |
| Merck Sharp & Dohme LLC | $26.23 | 2019-2022 | |
| Hologic Sales and Service, LLC | $24.31 | 2019 | |
| Supernus Pharmaceuticals, INC. | $18.83 | 2021 | |
| Circassia INC. | $14.77 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.69 | 2019 | |
| Neos Therapeutics, LP | $12.67 | 2022 | |
| Vertical Pharmaceuticals, LLC | $12.63 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.